UTHR
Income statement / Annual
Last year (2024), United Therapeutics Corporation's total revenue was $2.88 B,
an increase of 23.63% from the previous year.
In 2024, United Therapeutics Corporation's net income was $1.20 B.
See United Therapeutics Corporation,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$2.88 B |
$2.33 B |
$1.94 B |
$1.69 B |
$1.48 B |
$1.45 B |
$1.63 B |
$1.73 B |
$1.60 B |
$1.47 B |
| Cost of Revenue |
$309.70 M
|
$257.50 M
|
$146.70 M
|
$122.50 M
|
$108.10 M
|
$117.60 M
|
$198.70 M
|
$105.70 M
|
$72.70 M
|
$69.04 M
|
| Gross Profit |
$2.57 B
|
$2.07 B
|
$1.79 B
|
$1.56 B
|
$1.38 B
|
$1.33 B
|
$1.43 B
|
$1.62 B
|
$1.53 B
|
$1.40 B
|
| Gross Profit Ratio |
0.89
|
0.89
|
0.92
|
0.93
|
0.93
|
0.92
|
0.88
|
0.94
|
0.95
|
0.95
|
| Research and Development Expenses |
$481.00 M
|
$408.00 M
|
$322.90 M
|
$540.10 M
|
$357.70 M
|
$1.18 B
|
$357.90 M
|
$264.60 M
|
$147.60 M
|
$245.10 M
|
| General & Administrative Expenses |
$542.30 M
|
$395.30 M
|
$416.20 M
|
$402.60 M
|
$369.00 M
|
$275.50 M
|
$206.70 M
|
$265.80 M
|
$232.20 M
|
$358.32 M
|
| Selling & Marketing Expenses |
$96.30 M
|
$81.80 M
|
$70.80 M
|
$64.40 M
|
$54.90 M
|
$60.70 M
|
$59.10 M
|
$64.30 M
|
$84.60 M
|
$94.30 M
|
| Selling, General & Administrative Expenses |
$638.60 M
|
$477.10 M
|
$487.00 M
|
$467.00 M
|
$423.90 M
|
$336.20 M
|
$265.80 M
|
$330.10 M
|
$316.80 M
|
$452.61 M
|
| Other Expenses |
$71.10 M
|
$0.00
|
-$40.20 M
|
$42.20 M
|
$49.30 M
|
$22.60 M
|
-$7.70 M
|
$13.20 M
|
$2.40 M
|
$157,000.00
|
| Operating Expenses |
$1.19 B
|
$885.10 M
|
$809.90 M
|
$1.01 B
|
$781.60 M
|
$1.52 B
|
$623.70 M
|
$594.70 M
|
$464.40 M
|
$697.71 M
|
| Cost And Expenses |
$1.50 B
|
$1.14 B
|
$956.60 M
|
$1.13 B
|
$889.70 M
|
$1.64 B
|
$822.40 M
|
$700.40 M
|
$537.10 M
|
$766.75 M
|
| Interest Income |
$199.10 M
|
$162.70 M
|
$45.20 M
|
$16.70 M
|
$28.60 M
|
$44.20 M
|
$28.60 M
|
$10.90 M
|
$3.50 M
|
$0.00
|
| Interest Expense |
$42.90 M
|
$59.30 M
|
$32.40 M
|
$18.60 M
|
$23.50 M
|
$44.20 M
|
$13.90 M
|
$9.00 M
|
$3.90 M
|
$4.74 M
|
| Depreciation & Amortization |
$72.50 M
|
$53.20 M
|
$51.30 M
|
$49.90 M
|
$49.90 M
|
$45.90 M
|
$35.90 M
|
$31.00 M
|
$31.60 M
|
$32.92 M
|
| EBITDA |
$1.65 B |
$1.39 B |
$1.04 B |
$736.80 M |
$646.30 M |
-$74.90 M |
$838.40 M |
$1.05 B |
$1.09 B |
$1.08 B |
| EBITDA Ratio |
0.57
|
0.6
|
0.51
|
0.36
|
0.45
|
-0.08
|
0.51
|
0.6
|
0.67
|
0.48
|
| Operating Income Ratio |
0.48
|
0.51
|
0.51
|
0.33
|
0.4
|
-0.13
|
0.49
|
0.47
|
0.66
|
0.48
|
| Total Other Income/Expenses Net |
$162.00 M
|
$89.40 M
|
-$29.10 M
|
$38.00 M
|
$45.30 M
|
$22.60 M
|
-$46.50 M
|
-$45.40 M
|
-$1.50 M
|
$345.42 M
|
| Income Before Tax |
$1.54 B
|
$1.27 B
|
$950.60 M
|
$593.90 M
|
$638.90 M
|
-$165.00 M
|
$758.90 M
|
$769.50 M
|
$1.06 B
|
$1.04 B
|
| Income Before Tax Ratio |
0.53
|
0.55
|
0.49
|
0.35
|
0.43
|
-0.11
|
0.47
|
0.45
|
0.66
|
0.71
|
| Income Tax Expense |
$343.90 M
|
$289.50 M
|
$223.30 M
|
$118.10 M
|
$124.10 M
|
-$60.50 M
|
$169.70 M
|
$351.60 M
|
$346.50 M
|
$392.80 M
|
| Net Income |
$1.20 B
|
$984.80 M
|
$727.30 M
|
$475.80 M
|
$514.80 M
|
-$104.50 M
|
$589.20 M
|
$417.90 M
|
$713.70 M
|
$651.64 M
|
| Net Income Ratio |
0.42
|
0.42
|
0.38
|
0.28
|
0.35
|
-0.07
|
0.36
|
0.24
|
0.45
|
0.44
|
| EPS |
26.44 |
21.04 |
15.98 |
10.6 |
11.65 |
-2.39 |
13.54 |
9.5 |
16.29 |
14.17 |
| EPS Diluted |
24.64 |
19.81 |
15 |
10.06 |
11.54 |
-2.39 |
13.39 |
9.31 |
15.25 |
12.72 |
| Weighted Average Shares Out |
$45.20 M
|
$46.80 M
|
$45.50 M
|
$44.90 M
|
$44.20 M
|
$43.80 M
|
$43.50 M
|
$44.00 M
|
$43.80 M
|
$46.00 M
|
| Weighted Average Shares Out Diluted |
$48.50 M
|
$49.70 M
|
$48.50 M
|
$47.30 M
|
$44.60 M
|
$43.80 M
|
$44.00 M
|
$44.90 M
|
$46.80 M
|
$51.22 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
